Yasser is an expert in human immunology and cell biology. He has developed a research portfolio spanning molecular and cellular immunology, stem cells immunomodulation, biomarkers in translational and personalised medicine. Areas of particular interest include innate and adaptive immune responses in cancer, rheumatological disorders and regenerative medicine. Using primary derived cells, the phenotype and function of cells relating to specific diseases and states of inflammation are characterised. Specialist techniques of interest are flow cytometry, RT PCR and NanoString genetic profiling.

“Understanding of Molecular & Cellular immunological interactions is fundamental to develop novel, safe and innovative therapies for diseases. We offer a wide range of immune testing, immunophenotyping and cellular functions as well as biomarker discovery and validation in medical translational and non-clinical tenacities”.

Dr Yasser El-Sherbiny

Current Research Areas & Activities

Understanding and Discovery of predictive biomarkers in rheumatological disorders.

Interferon pathway regulation/dysregulation &implications on immune signalling

Mesenchymal Stem cells immunomodulation vs regeneration, towards innovative immunotherapeutic tactics




Specialises in


Patient Stratification

Interferon pathway,

Genetically Modified Cells
Immunomodulation of Stem Cells
Exosomes and Microvesicles
Application of Biomaterials
Innovative Cell therapy

Innate Immune Response


Pathology and Therapeutics

Selected Publications

Srikanth S, Woo JS, Wu B, El-Sherbiny YM, Leung J, Chupradit K, Rice L, Seo GJ, Calmettes G, Ramakrishna C, Cantin E, An DS, Sun R, Wu TT, Jung JU, Savic S, Gwack Y. The Ca(2+) sensor STIM1 regulates the type I interferon response by retaining the signaling adaptor STING at the endoplasmic reticulum. Nat Immunol. 2019 Feb;20(2):152-162. https://dx.doi.org/10.1038/s41590-018-0287-8.

El-Sherbiny YM, El-Jawhari JJ, Moseley TA, McGonagle D, Jones E. T cell immunomodulation by clinically used allogeneic human cancellous bone fragments: a potential novel immunotherapy tool. Sci Rep. 2018 Sep 10;8(1):13535. https://dx.doi.org/10.1038/s41598-018-31979-1.

Md Yusof MY, Psarras A, El-Sherbiny YM, Hensor EMA, Dutton K, Ul-Hassan S, Zayat AS, Shalbaf M, Alase A, Wittmann M, Emery P, Vital EM. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Ann Rheum Dis. 2018 Oct;77(10):1432-1439. https://dx.doi.org/10.1136/annrheumdis-2018-213386.

El-Sherbiny YM, Psarras A, Md Yusof MY, Hensor EMA, Tooze R, Doody G, Mohamed AAA, McGonagle D, Wittmann M, Emery P, Vital EM. A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features. Sci Rep. 2018 Apr 11;8(1):5793. https://dx.doi.org/10.1038/s41598-018-24198-1.

Liakouli V, Elies J, El-Sherbiny YM, Scarcia M, Grant G, Abignano G, Derrett-Smith EC, Esteves F, Cipriani P, Emery P, Denton CP, Giacomelli R, Mavria G, Del Galdo F. Scleroderma fibroblasts suppress angiogenesis via TGF-ß/caveolin-1 dependent secretion of pigment epithelium-derived factor. Ann Rheum Dis. 2018 Mar;77(3):431-440. https://dx.doi.org/10.1136/annrheumdis-2017-212120.